|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2001
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis
1 Dépt de Médecine et Laboratoire d'Investigation Clinique H.J. Tagnon, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium and 2 Service de Pneumologie et Oncologie Thoracique, Centre Hospitalo-Universitaire Calmette, Lille, France
CORRESPONDENCE: J.P. Sculier, Service de Médecine, Institut Jules Bordet, 1 rue Héger Bordet, B-;1000, Brussels, Belgium. Fax: 32 25343756
Keywords: lung cancer, meta-analysis, p53, prognosis, survival, systemic review
Received: July 7, 2000
Accepted April 12, 2001
Abstract
The role of p53, as a prognostic factor for survival in lung cancer, is controversial and the purpose of the present systematic review of the literature is to determine this effect.
Published studies were identified with the objective to aggregate the available survival results after a methodological assessment using a scale specifically designed by the European Lung Cancer Working Party (ELCWP). To be eligible, a study had to deal with p53 assessment in lung cancer (primary site) only, and to provide a survival comparison according to the p53 status.
Among the 74 eligible papers, 30 identified p53 abnormalities as a univariate statistically significant poor prognostic factor and 56 provided sufficient data to allow survival results aggregation. There was no significant difference between the trials that either showed or did not show a prognostic effect of p53 according to the methodological score or to the laboratory technique used. The studies were categorized by histology, disease stage, treatment and laboratory technique. Combined hazard ratios suggested that an abnormal p53 status had an unfavourable impact on survival: in any stage nonsmall cell lung cancer (NSCLC) the mean (95% confidence interval) was 1.44 (1.20–1.72) (number of studies included in the subgroup was 11), 1.50 (1.32–1.70) in stages I–II NSCLC (n=19), 1.68 (1.23–2.29) in stages I–IIIB NSCLC (n=5), 1.68 (1.30–2.18) in stages III–IV NSCLC (n=9), 1.48 (1.29–1.70) in surgically resected NSCLC (n=20), 1.37 (1.02–1.85) in squamous cell carcinoma (n=9), 2.24 (1.70–2.95) in adenocarcinoma (n=9), 1.57 (1.28–1.91) for a positive immunohistochemistry with antibody 1801 (n=8), 1.25 (1.09–1.43) for a positive immunohistochemistry with antibody DO-;7 (n=16), and 1.65 (1.35–2.00) for an abnormal molecular biology test (n=13). Data were insufficient to determine the prognostic value of p53 in small cell lung cancer.
In each subgroup of nonsmall cell lung cancer, p53 abnormal status was shown to be associated with a poorer survival prognosis.
This article has been cited by other articles:
|
|
 |
|
  L. Chhatwani, E. Cabebe, and H. A. Wakelee Adjuvant Treatment of Resected Lung Cancer Proceedings of the ATS, April 15, 2009; 6(2): 194 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. G. Rothberg, M. B. Bracken, and D. L. Rimm Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis J Natl Cancer Inst, April 1, 2009; 101(7): 452 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Sculier Prognostic Factors and Implications of Positron Emission Tomography ASCO Educational Book, January 1, 2009; 2009(1): 469 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. McDonald, C. E. Pelloski, A. Ledoux, M. Sun, G. Raso, R. Komaki, I. I. Wistuba, B. N. Bekele, and K. Aldape Elevated Phospho-S6 Expression Is Associated with Metastasis in Adenocarcinoma of the Lung Clin. Cancer Res., December 1, 2008; 14(23): 7832 - 7837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Jeong, H.-W. Lee, J. H. Han, S. Y. Kang, J.-H. Choi, Y. M. Jung, H. Choi, Y. T. Oh, K. J. Park, S. C. Hwang, et al. Low Expression of Bax Predicts Poor Prognosis in Resected Non-small Cell Lung Cancer Patients with Non-squamous Histology Jpn. J. Clin. Oncol., October 1, 2008; 38(10): 661 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kandioler, G. Stamatis, W. Eberhardt, S. Kappel, S. Zochbauer-Muller, I. Kuhrer, M. Mittlbock, R. Zwrtek, C. Aigner, C. Bichler, et al. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer. J. Thorac. Cardiovasc. Surg., May 1, 2008; 135(5): 1036 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-S. Tsao, S. Aviel-Ronen, K. Ding, D. Lau, N. Liu, A. Sakurada, M. Whitehead, C.-Q. Zhu, R. Livingston, D. H. Johnson, et al. Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non Small-Cell Lung Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5240 - 5247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Schwartz and D. E. Henson Diagnostic Surgical Pathology in Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 78S - 93S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Schwartz, G. M. Prysak, C. H. Bock, and M. L. Cote The molecular epidemiology of lung cancer Carcinogenesis, March 1, 2007; 28(3): 507 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Kyzas, D. Denaxa-Kyza, and J. P. A. Ioannidis Quality of Reporting of Cancer Prognostic Marker Studies: Association With Reported Prognostic Effect J Natl Cancer Inst, February 7, 2007; 99(3): 236 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Berghmans, M Paesmans, C Mascaux, B Martin, A-P Meert, A Haller, J-J Lafitte, and J-P Sculier Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis Ann. Onc., November 1, 2006; 17(11): 1673 - 1676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C-Q Zhu, W Shih, C-H Ling, and M-S Tsao Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J. Clin. Pathol., August 1, 2006; 59(8): 790 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Are and A. R. Shaha Anaplastic Thyroid Carcinoma: Biology, Pathogenesis, Prognostic Factors, and Treatment Approaches Ann. Surg. Oncol., April 1, 2006; 13(4): 453 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Hayden, P. Cote, and C. Bombardier Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med, March 21, 2006; 144(6): 427 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Kyzas, K. T. Loizou, and J. P. A. Ioannidis Selective Reporting Biases in Cancer Prognostic Factor Studies J Natl Cancer Inst, July 20, 2005; 97(14): 1043 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Comin, L. Messerini, L. Novelli, V. Boddi, and S. Dini KI-67 Antigen Expression Predicts Survival and Correlates with Histologic Subtype in the WHO Classification of Thymic Epithelial Tumors International Journal of Surgical Pathology, October 1, 2004; 12(4): 395 - 400. [Abstract] [PDF]
|
|
|
|
|
|
H.-S. Hsu, Y.-C. Wang, R.-C. Tseng, J.-W. Chang, J.-T. Chen, C.-M. Shih, C.-Y. Chen, and Y.-C. Wang CpG Island Methylation Is Responsible for p14ARF Inactivation and Inversely Correlates with p53 Overexpression in Resected Non-Small Cell Lung Cancer Clin. Cancer Res., July 15, 2004; 10(14): 4734 - 4741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gessner, C. Woischwill, A. Schumacher, U. Liebers, H. Kuhn, P. Stiehl, K. Jurchott, H.D. Royer, C. Witt, and G. Wolff Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer Eur. Respir. J., January 1, 2004; 23(1): 14 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A-P. Meert, B. Martin, P. Delmotte, T. Berghmans, J-J. Lafitte, C. Mascaux, M. Paesmans, E. Steels, J-M. Verdebout, and J-P. Sculier The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis Eur. Respir. J., October 1, 2002; 20(4): 975 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Brambilla and S. Spiro Highlights in lung cancer Eur. Respir. J., October 1, 2001; 18(4): 617 - 618. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |